Eugia Pharma’s facility gets USFDA’s nod

BL Hyderabad Bureau Updated - July 26, 2023 at 03:41 PM.
The inspection closed with zero observations and a classification of No Action Indicated (NAI).

The United States Food and Drug Administration (US FDA) has approved a Formulation manufacturing facility of Eugia Pharma Specialities Ltd., a wholly owned subsidiary of Aurobindo Pharma.

Sign up for newsletters, unlock features and do more on The Hindu
LOG IN
Support our reporting.
SUBSCRIBE NOW

The US regulator inspected Unit I, a Formulation manufacturing facility of Eugia Pharma Specialities situated at Koltur Village, Shameerpet, Medchal District, Telangana, from July 17-26, 2023. 

Also read: Eugia Pharma receives USFDA approval for Plerixafor injection

“The inspection closed with zero observations and a classification of No Action Indicated (NAI),” Hyderabad-based Aurobindo said in a release.

Published on July 26, 2023 10:11
Tags

This is a Premium article available exclusively to our subscribers.

Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

Subscribe
If you're already a subscriber
Access just this article

You have reached your free article limit.

Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

Subscribe
If you're already a subscriber
Access just this article

You have reached your free article limit.
Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

Subscribe
or read this article by Downloading TheHindu Businessline News app
If you're already a subscriber
Access just this article

TheHindu Businessline operates by its editorial values to provide you quality journalism.

Support our reporting.
Subscribe
This is your last free article.
to read unlimited content from TheHindu Businessline
Subscribe
Stay updated on Markets,Economy, Agri & more.
Get TheHindu Businessline News App on
Recommended Articles